GLP-1 'weight loss shot' TikToks: what the science actually says
Quick answer
The creator is self-administering what appears to be a tirzepatide-based injectable, either compounded or brand-name, combined with vitamin D in a single syringe, under the supervision of an aesthetic medicine provider. She reports 12 pounds of weight loss and describes a nausea and vomiting episode consistent with high-fat food intake during slowed gastric emptying, a recognized GI adverse effect of GIP/GLP-1 dual agonists. Her practice of suspending medication during travel without described dose re-titration on restart is clinically relevant and potentially the source of her reported GI episode.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @dadollsamira2 actually say?
The creator documented her self-administered injection of what she calls "Zepit type" mixed with vitamin D, claimed she lost 12 pounds, and offered personal safety advice about eating before injections. She said she experienced nausea and vomiting after injecting on an empty stomach following a break from the medication. She disclosed she was off the shot during a trip to Jamaica and returned to it. She tagged a provider she calls "Dr. Rhoda" and avoided showing the vial on camera, citing TikTok's content policies.
A few things worth flagging immediately: she never clarified whether this is brand-name tirzepatide (Zepbound or Mounjaro) or a compounded version. That distinction matters legally, clinically, and from a safety standpoint, and she glossed right over it.
Does the science back this up?
The core premise, that tirzepatide produces meaningful weight loss, is well-supported. The bigger questions are around her specific framing of side effects and her vitamin D mixing claim.
Tirzepatide's efficacy is not in dispute. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants on 15 mg tirzepatide lost an average of 20.9% of body weight over 72 weeks. Losing 12 pounds is plausible, especially early in treatment.
The nausea and vomiting she described after eating McDonald's on an empty stomach mid-cycle is consistent with how GLP-1/GIP dual agonists work. These drugs slow gastric emptying significantly. Eating high-fat, calorie-dense food while gastric motility is suppressed is a well-documented trigger for GI distress (Nauck et al., 2021, Nature Reviews Drug Discovery). She is not wrong here. She is describing pharmacology correctly, even if she doesn't know the mechanism.
The vitamin D mixing claim is where things get murky. There is no peer-reviewed evidence supporting mixing tirzepatide with vitamin D in a single injection. This is not a standard pharmaceutical practice for either compound.
What did they get wrong (or right)?
Credit where it's due: her core advice, "eat the way you need to eat" before injecting, is clinically sound. GI side effects on GLP-1-class drugs are strongly correlated with dietary choices, and starting back after a medication break with a high-fat meal is genuinely asking for trouble. She learned this the hard way and reported it honestly.
What she got wrong, or at least dangerously incomplete, is the vitamin D mixing. She presented it casually as if it's a routine thing. It is not. Combining compounds in a single syringe without pharmaceutical guidance raises sterility, stability, and dosing accuracy concerns. No compounding pharmacy protocol I'm aware of recommends this as a standard patient practice. If her provider instructed this, that provider should be explaining the rationale on camera, not leaving it to a 36K-view TikTok to normalize.
She also said she had "no side effects," then immediately described vomiting. That is a side effect. It's a minor framing problem but it could mislead viewers into thinking they should have a completely smooth experience and that vomiting means something is wrong uniquely with them.
What should you actually know?
If you are considering a tirzepatide-based weight loss program, a few things the video does not tell you are worth knowing.
- Compounded tirzepatide and brand-name Zepbound or Mounjaro are not interchangeable. The FDA has raised concerns about compounded versions, including inconsistent dosing and lack of the same safety data (FDA Drug Shortages guidance, 2023-2024).
- GI side effects, including nausea, vomiting, and diarrhea, affect a significant portion of users. In SURMOUNT-1, nausea occurred in up to 31% of participants on the highest dose. These are not rare edge cases.
- Stopping and restarting GLP-1 class medications, as she did for her trip, typically requires dose re-titration to reduce side effects. Her provider should be guiding that process, not the patient improvising.
- Mixing any injectable compound at home without explicit pharmacy or prescriber guidance is a sterility and dosing risk. Do not normalize this based on a social media video.
- Weight loss on these medications tends to plateau and can reverse after stopping. The 12-pound figure is a snapshot, not a guaranteed trajectory.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 'weight loss shot' TikToks: what the science actually says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 'weight loss shot' TikToks: what the science actually says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator is self-administering what appears to be a tirzepatide-based injectable, either compounded or brand-name, combined with vitamin D in a single syringe, under the supervision of an aesthetic medicine provider.
FormBlends verdict
The creator is self-administering what appears to be a tirzepatide-based injectable, either compounded or brand-name, combined with vitamin D in a single syringe, under the supervision of an aesthetic medicine provider. She reports 12 pounds of weight loss and describes a nausea and vomiting episode consistent with high-fat food intake during slowed gastric emptying, a recognized GI adverse effect of GIP/GLP-1 dual agonists. Her practice of suspending medication during travel without described dose re-titration on restart is clinically relevant and potentially the source of her reported GI episode.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is self-administering what appears to be a tirzepatide-based injectable, either compounded or brand-name, combined with vitamin D in a single syringe, under the supervision of an aesthetic medicine provider. She reports 12 pounds of weight loss and describes a nausea and vomiting episode consistent with high-fat food intake during slowed gastric emptying, a recognized GI adverse effect of GIP/GLP-1 dual agonists. Her practice of suspending medication during travel without described dose re-titration on restart is clinically relevant and potentially the source of her reported GI episode.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found tirzepatide 15 mg produced average weight loss of 20.9% over 72 weeks, so early losses like 12 pounds are plausible but not guaranteed.
- Up to 31% of tirzepatide users at higher doses experienced nausea in clinical trials; vomiting is a side effect, not an anomaly, even if the creator framed it as an exception.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found tirzepatide 15 mg produced average weight loss of 20.9% over 72 weeks, so early losses like 12 pounds are plausible but not guaranteed.
- Up to 31% of tirzepatide users at higher doses experienced nausea in clinical trials; vomiting is a side effect, not an anomaly, even if the creator framed it as an exception.
- Gastric emptying is significantly slowed by GLP-1/GIP dual agonists, making high-fat meals a documented trigger for GI distress, exactly what the creator described after eating McDonald's.
- The FDA has flagged concerns about compounded GLP-1 drugs, including inconsistent potency and lack of equivalent safety data to brand-name products; compounded tirzepatide is not the same as Zepbound or Mounjaro.
- Mixing injectables at home, such as tirzepatide with vitamin D in one syringe, is not a standard or studied practice and introduces sterility and dosing risks that a social media video cannot adequately address.
- Restarting GLP-1 class medications after a break typically requires dose re-titration per prescribing guidelines; skipping this step is likely what caused her post-Jamaica vomiting episode.
- Weight regain after stopping GLP-1 medications is well-documented; a 12-pound loss figure shared mid-treatment does not reflect long-term outcomes without continued use and lifestyle support.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
mimii🫶🏽 · TikTok creator
36.0K views on this video
Do my weightloss shot with me🤍 @Dermacare Wellnes & Aesthetics • #foryoupage #fypシ゚viral #weightloss #weightlossmotivation #weightlossshots #dadollsamira2
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by mimii🫶🏽, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.